VERTEX PHARMACEUTICALS INC reported first-quarter adjusted profit of $4.47 per share, beating LSEG estimates of $4.31 per share. Revenue rose 8% to $2.99 billion, driven by a 687% sales surge for the new cystic fibrosis therapy Alyftrek. The results highlight Vertex's successful shift toward new treatments as its legacy blockbuster Trikafta missed analyst sales expectations.
Vertex beats profit estimates as new drug sales rise
Vertex reported adjusted profit of $4.47 per share as sales of its new cystic fibrosis drug Alyftrek rose. Total quarterly revenue reached $2.99 billion.
Xurve View
Insights:
Xurve View








